5 results
The primary objective of this pilot study is to evaluate the effects of 6 months of recombinant human IGF-I (rhIGF-I) treatment on the body composition.The secondary objective is to assess the effects of the treatment on the liver function,…
Primary objective:- To evaluate the efficacy of caplacizumab in combination with immunosuppressive therapy (IST) without therapeutic plasma exchange (TPE) inadults with immune mediated thrombotic thrombocytopenic purpura (iTTP)Secondary objectives:…
To evaluate the efficacy of GSK3511294 100 mg (SC) every 26 weeks versus maintaining existing treatment with either mepolizumabor benralizumab in participants with severe asthma with an eosinophilic phenotype who have previously benefited from anti-…
Primary:To evaluate the efficacy of depemokimab 200 mg SC every 26 weeks compared with mepolizumab 300 mg SC every 4 weeks in participants with relapsing or refractory EGPA receiving SoC therapySecondary:- To evaluate the efficacy of depemokimab 200…
Primary objective:To evaluate the efficacy of depemokimab 100mg SC + SoC compared to placebo + SoC at Week 52 in participants with a diagnosis of CRSwNP.Secondary Objectives:To evaluate the efficacy of depemokimab 100 mg SC + SoC compared to placebo…